Kex2 Inhibitors

Chemical inhibitors of Kex2 play a significant role in impeding its proteolytic functions by various mechanisms. The irreversible inhibitor Decanoyl-RVKR-CMK targets the serine residue in the active site of Kex2, covalently modifying it, which results in the permanent loss of enzymatic activity. Similarly, K777 binds covalently to the active site cysteine of Kex2, halting its proteolytic activity. Another example is E-64, which, although known primarily as a cysteine protease inhibitor, can inhibit Kex2 by occupying its active site, thus denying access to substrates that Kex2 would typically cleave. Leupeptin operates by forming a reversible bond with the active site of Kex2, effectively obstructing the cleavage of substrates. Furthermore, despite being an aspartyl protease inhibitor, Pepstatin A can inhibit the activity of Kex2 due to the aspartyl residue present within the protease's active site, hindering its function.

In addition to these, antipain, a peptide aldehyde inhibitor, interferes with Kex2 activity through interaction with its active site, while chymostatin binds to the active site serine of Kex2, preventing peptide bond hydrolysis. MG-132, a reversible inhibitor of the proteasome and calpain, can indirectly inhibit Kex2 by obstructing the proteolytic degradation pathways necessary for its activation. Similarly, lactacystin, a natural product, inhibits proteasome activity, which is crucial for the proteolytic maturation of Kex2, thereby reducing Kex2 activity. AEBSF, another serine protease inhibitor, irreversibly inhibits Kex2 by covalently modifying the serine within the active site. Z-FA-FMK, which is based on a fluoromethylketone, can inhibit Kex2 by binding to the active site cysteine residue. Lastly, MDL-28170, a calpain inhibitor known to cross-react with other cysteine proteases, can inhibit Kex2 by attaching to its active site, preventing the processing of its substrates. Each of these chemicals acts as a functional inhibitor by directly interacting with the active site or involved pathways of Kex2, thereby reducing or completely abolishing its protease activity.